Search Results for: GNPX

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, on Wednesday announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 5,000,000 shares of common stock, par value $0.001 per share, at an offering price of … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $17,500,000 Common Stock Offering At-The-Market”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced its entry into an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh for Potentially Curative Gene Therapy Candidate for Diabetes”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its February 4, 2020 receipt of notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the company has regained compliance with the minimum bid price requirement under Nasdaq Listing … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Meets Nasdaq Minimum Bid Price Requirement, Regains Compliance”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provided a clinical update and focus for its Oncoprex(TM) immunogene therapy program for 2020. According to the update, Genprex will prioritize the development of Oncoprex in combination with osimertinib for the … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Focus Clinical Efforts on Oncoprex(TM) in Combination with Osimertinib for Treatment of Non-Small Cell Lung Cancer”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that it will present at the Noble Capital Markets 16th Annual Investor Conference. Genprex’s presentation is scheduled to take place at 1:30 p.m. EST on Monday, February 17, 2020, at … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at NobleCon16 Investor Conference”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that, in a recent study, independent researchers reported that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, is a potential target and biomarker for … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Independent Research Findings on TUSC2 as a Potential Target and Biomarker for Thyroid Carcinoma”

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced the closing of its common stock offering priced at-the-market under Nasdaq rules. Genprex sold a total of 7,620,000 shares of its … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Closes $8M At-The-Market Offering”

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced its entry into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock. According … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $8M Common Stock Offering At-The-Market”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that the U.S Food and Drug Administration (FDA) has granted Fast Track Designation for Genprex’s Oncoprex(TM) immunogene therapy in combination with EGFR inhibitor osimertinib (AstraZeneca’s Tagrisso(R)). Tagrisso(R), with worldwide sales … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Receipt of U.S. FDA Fast Track Designation for Immunogene Therapy that Targets Lung Cancer”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its plans to attend and present at the Biotech Showcase(TM) 2020, to be held at the Hilton San Francisco Union Square in San Francisco from January 13–15, 2020. Genprex’s President … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Biotech Showcase(TM) 2020 in San Francisco”